MISTIE INTRACEREBRAL HEMORRHAGE TRIAL

Does faster clot removal give better patient outcomes in ICH?

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
Steve Mayo

Steve Mayo

President of Emissary International (www.Emissary.com) the CRO supporting CLEAR and MISTIE programs. Steve is known in the CRO industry as "SuperMonitor" due to an article he wrote many years ago about life as a clinical research associate.

Steve enjoys photography, travelling to far-away places, hiking with his son, and web design. He maintains several websites: http://www.Troop-201.com and http://OmniVesting.com
178

Dr. David Newman-Toker and the Brain Injury Outcomes (BIOS) coordinating center at Johns Hopkins University are happy to announce that The National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health (NIH), has awarded funding for the AVERT clinical trial (FAIN U01DC013778). AVERT (Acute Video-oculography for vertigo in Emergency rooms for Rapid Triage) is a randomized controlled trial evaluating the algorithmic application of a diagnostic medical device (video-oculography or VOG)  in the triage of patients presenting to hospital emergency departments with vertigo and dizziness.

The study is expected to randomize 226 patients across 3 U.S.-based clinical sites. The study has been deemed a non-significant risk device trial by the U.S. FDA as it involves a new (investigational) application of this device. VOG devices are currently FDA-approved for measuring eye movements in the assessment of vestibular conditions; they have not been used extensively in the emergency department setting prior to this trial. The study is currently under review by the Institutional Review Boards at the participating sites and is expected to start enrolling next year.

Continue reading
396

The 12th Annual Neurocritical Care Society (NCS) Meeting will be held this year in Seattle on 11-14 September. There will be a comprehensive session on intracerebral hemorrhage, including reviews of exciting recent advances in the translational, epidemiological and clinical areas. 

Friday’s focus on ICH will provide cutting-edge science, clarity in the practice of complex clinical problems, and maybe even stir up a little controversy. Our MISTIE/CLEAR Lead Investigator, Dr. Daniel F. Hanley, will be speaking as well, on interventional treatment so you don't want to miss it. Click here for details.

1079

The 12th Annual Neurocritical Care Society (NCS) Meeting will be held this year in Seattle on 11-14 September. There will be a comprehensive session on intracerebral hemorrhage, including reviews of exciting recent advances in the translational, epidemiological and clinical areas. 

Friday’s focus on ICH will provide cutting-edge science, clarity in the practice of complex clinical problems, and maybe even stir up a little controversy. Our MISTIE/CLEAR Lead Investigator, Dr. Daniel F. Hanley, will be speaking as well, on interventional treatment so you don't want to miss it. Click here for details.

419

In collaboration with the Johns Hopkins University School of Medicine Office of Continuing Medical Education, we now provide continuing medical education (CME) credits, specifically AMA PRA Category 1 Credit™, for completing the online MISTIE-III investigator training courses.   You may earn up to 9 hours, but you must take a specific set of courses. You must also be a registered user of this site.

977

We are delighted to report that the first patient has now enrolled in the MISTIE III intracerebral hemorrhage trial! In the race to be the first out-of-the-gate, the honor goes to Hartford Hospital.

Dr. Inam Kureshi and his team at Hartford enrolled patient #1 at 17:02 on 30-Dec-2013, marking the official start of the study period. Congratulations go out to the Hartford team which includes the coordinator, Sara Jasak, RN, and the neurointensivist, Dr. Robert Brown. This was the 12th patient to be screened at this site since the site was activated on 11-December. We are especially proud of how Sara Jasak has entered the clinical data in near real-time; just a few days into the acute treatment and we already have 54 final case form pages with no open queries! Way to go, Sara!

Continue reading

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368